Stian Knappskog

Neoadjuvant endocrine therapy with sequential palbociclib and chemotherapy based on Ki67 status in stage II-III breast cancer: an open-label, phase II study While neoadjuvant endocrine therapy (NET), with or without a CDK4/6 inhibitor, is an established treatment option for estrogen receptor-positive breast cancers, optimal patient selection and second-li...

Paper out, from the PETREMAC trial

www.thebreastonline.com/article/S096...

Webinar on breast cancer research (norwegian), for Driv, supported by @mohnfoundation.bsky.social & @unibergen.bsky.social

www.youtube.com/watch?v=22k9...

Letter for the article Triple-Negative Breast Cancer on the Rise: Brea | BCTT Letter for the article Triple-Negative Breast Cancer on the Rise: Breakthroughs and Beyond

Clearing up misunderstandings about TNBC.

www.dovepress.com/triple-negat...